The Journal of thoracic and cardiovascular surgery · 2025
Impact of residual mitral valve regurgitation following septal myectomy for obstructive hypertrophic cardiomyopathy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Qamar Younus, Schaff Hartzell V, Geske Jeffrey B, Dearani Joseph A, Giudicessi John R, Todd Austin, Ommen Steve R
Аннотация
OBJECTIVE: To evaluate the impact of residual mitral valve (MV) regurgitation (MR) in patients with obstructive hypertrophic cardiomyopathy immediately after myectomy on late survival and the risk of MV reintervention.
METHODS: From October 2001 to February 2024, 3061 patients with hypertrophic cardiomyopathy and dynamic left ventricular outflow tract obstruction underwent septal myectomy. A 1:1 propensity score matching was performed between patients with mild or trivial/no residual MR immediately after cardiopulmonary bypass and patients with moderate or greater residual MR. Long-term survival, MR progression, and the incidence of MV reintervention were analyzed.
RESULTS: Postbypass moderate or greater residual MR was present in 398 patients (13.9%). Matching yielded 398 pairs, with no differences in age (62.1 years vs 61.9 years, P = .397), nor in median peak left ventricular outflow tract gradient on predismissal echocardiography (3 [0-9] mm Hg vs 3 [0-10] mm Hg, P = .585). Late incidence of moderate-severe or greater MR was greater in those with residual MR (15 years: 48.0% vs 11.9%, P = .002), and the incidence of subsequent MV intervention at 15 years was 3-fold greater in those with intraoperative residual MR (14.0% vs 3.9%, P = .007). However, the overall survival of the 2 groups was similar (P = .48).
CONCLUSIONS: Residual MR after septal myectomy is not associated with early or late mortality. However, beyond 5 years' postoperatively, patients with moderate or greater residual MR experience accelerated rates of recurrent MR and require MV reintervention. Residual MR may be attributable to unrecognized mild intrinsic MV disease that progresses late postoperatively.
METHODS: From October 2001 to February 2024, 3061 patients with hypertrophic cardiomyopathy and dynamic left ventricular outflow tract obstruction underwent septal myectomy. A 1:1 propensity score matching was performed between patients with mild or trivial/no residual MR immediately after cardiopulmonary bypass and patients with moderate or greater residual MR. Long-term survival, MR progression, and the incidence of MV reintervention were analyzed.
RESULTS: Postbypass moderate or greater residual MR was present in 398 patients (13.9%). Matching yielded 398 pairs, with no differences in age (62.1 years vs 61.9 years, P = .397), nor in median peak left ventricular outflow tract gradient on predismissal echocardiography (3 [0-9] mm Hg vs 3 [0-10] mm Hg, P = .585). Late incidence of moderate-severe or greater MR was greater in those with residual MR (15 years: 48.0% vs 11.9%, P = .002), and the incidence of subsequent MV intervention at 15 years was 3-fold greater in those with intraoperative residual MR (14.0% vs 3.9%, P = .007). However, the overall survival of the 2 groups was similar (P = .48).
CONCLUSIONS: Residual MR after septal myectomy is not associated with early or late mortality. However, beyond 5 years' postoperatively, patients with moderate or greater residual MR experience accelerated rates of recurrent MR and require MV reintervention. Residual MR may be attributable to unrecognized mild intrinsic MV disease that progresses late postoperatively.